Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments Life Science Investing
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer Pharmaceutical Investing
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease Life Science Investing
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy Life Science Investing
Incyte Announces Positive CHMP Opinion for Minjuvi® for the Treatment of Relapsed or Refractory Follicular Lymphoma Life Science Investing
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. Life Science Investing
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results Pharmaceutical Investing
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results Life Science Investing
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity Life Science Investing
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer Pharmaceutical Investing
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update Life Science Investing
